androgen deprivation therapy-Tata Memorial Centre-prostate cancer

Androgen deprivation therapy (ADT) in the context of the Tata Memorial Centre's RELAX trial (NCT05938010) refers to a treatment strategy for high-risk non-metastatic prostate cancer. The trial investigates a de-escalated approach where the standard 24-month duration of ADT is reduced to 9 months and intensified with 6 months of androgen receptor-targeted agents (ARTA), such as abiraterone or enzalutamide. This regimen is administered alongside curative-intent radiotherapy to the prostate and pelvic nodes. The primary objective is to evaluate whether this intensified, shorter-duration hormonal therapy can maintain oncological efficacy while significantly reducing the long-term side effects associated with prolonged testosterone suppression, such as cardiovascular disease, metabolic syndrome, and impaired quality of life.

Other names

Reduced duration ADT + ARTAReduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer